Analysts Set aTyr Pharma, Inc. (NASDAQ:ATYR) Target Price at $25.67

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have earned a consensus recommendation of “Hold” from the eight brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $25.6667.

A number of research firms have recently commented on ATYR. Freedom Capital raised aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. Finally, Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday.

Institutional Investors Weigh In On aTyr Pharma

Several large investors have recently added to or reduced their stakes in ATYR. Millennium Management LLC boosted its stake in aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after buying an additional 1,231,052 shares during the period. Goldman Sachs Group Inc. boosted its stake in aTyr Pharma by 46.0% during the first quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company’s stock valued at $1,155,000 after buying an additional 120,496 shares during the period. Creative Planning bought a new stake in aTyr Pharma during the second quarter valued at $74,000. JPMorgan Chase & Co. bought a new stake in aTyr Pharma during the second quarter valued at $208,000. Finally, Legal & General Group Plc bought a new stake in aTyr Pharma during the second quarter valued at $49,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Price Performance

aTyr Pharma stock opened at $0.53 on Thursday. aTyr Pharma has a one year low of $0.40 and a one year high of $7.29. The business has a fifty day moving average price of $0.79 and a 200-day moving average price of $0.80. The firm has a market capitalization of $52.03 million, a P/E ratio of -0.73 and a beta of 0.66.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Sell-side analysts expect that aTyr Pharma will post -0.66 earnings per share for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.